Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Maria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, Ib Jarle Christensen, Kirsten Grunnet, Ulrik Lassen, Søren Friis & Hans Skovgaard Poulsen. (2018) Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. Cancer Investigation 36:9-10, pages 512-519.
Read now
Read now
Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm & Hans Skovgaard Poulsen. (2018) Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Investigation 36:2, pages 165-174.
Read now
Read now
Omar Abdel-Rahman & Mona Fouad. (2015) Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review. Expert Review of Neurotherapeutics 15:11, pages 1255-1270.
Read now
Read now
Emilie Le Rhun, Sophie Taillibert & Marc C Chamberlain. (2015) Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics 15:6, pages 601-620.
Read now
Read now
Richard C Curry, Saurabh Dahiya, Vyshak Alva Venur, Jeffrey J Raizer & Manmeet S Ahluwalia. (2015) Bevacizumab in high-grade gliomas: past, present, and future. Expert Review of Anticancer Therapy 15:4, pages 387-397.
Read now
Read now
Kenneth F. Hofland, Steinbjørn Hansen, Morten Sorensen, Silke Engelholm, Henrik P. Schultz, Aida Muhic, Kirsten Grunnet, Anders Ask, Junia C. Costa, Charlotte Kristiansen, Carsten Thomsen, Hans Skovgaard Poulsen & Ulrik Lassen. (2014) Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Acta Oncologica 53:7, pages 939-944.
Read now
Read now
Mikael L Rinne, Eudocia Q Lee, Lakshmi Nayak, Andrew D Norden, Rameen Beroukhim, Patrick Y Wen & David A Reardon. (2013) Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opinion on Emerging Drugs 18:2, pages 137-153.
Read now
Read now
Articles from other publishers (43)
Thi-Anh-Thuy Tran, Young-Hee Kim, Thi-Hoang-Oanh Duong, JayaLakshmi Thangaraj, Tan-Huy Chu, Shin Jung, In-Young Kim, Kyung-Sub Moon, Young-Jin Kim, Tae-Kyu Lee, Chul Won Lee, Hyosuk Yun, Je-Jung Lee, Hyun-Ju Lee, Kyung-Hwa Lee & Tae-Young Jung. (2023) Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model. Frontiers in Immunology 13.
Crossref
Crossref
Ahmad Daher & Santosh Kesari. 2023. New Insights Into Glioblastoma. New Insights Into Glioblastoma
285
317
.
Ezgi Değerli, Gülin Alkan, Nihan Şentürk Öztaş, Şahin Bedir, Sümeyra Derin & Nebi Serkan Demirci. (2021) Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme. Journal of Oncology Pharmacy Practice 28:3, pages 746-749.
Crossref
Crossref
Zeynep HASİMOGLU, Zübeyde ERBAYRAKTAR & Reşat Serhat ERBAYRAKTAR. (2021) Investigation of the anti-tumor effects of bevacizumab on glioblastoma cells. Journal of Basic and Clinical Health Sciences 5:2, pages 110-114.
Crossref
Crossref
Stephen Shuford, Lindsay Lipinski, Ajay Abad, Ashley M Smith, Melissa Rayner, Lauren O’Donnell, Jeremy Stuart, Laszlo L Mechtler, Andrew J Fabiano, Jeff Edenfield, Charles Kanos, Stephen Gardner, Philip Hodge, Michael Lynn, Nicholas A Butowski, Seunggu J Han, Navid Redjal, Howland E Crosswell, Cecile Rose T Vibat, Lillia Holmes, Matthew Gevaert, Robert A Fenstermaker & Teresa M DesRochers. (2021) Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neuro-Oncology Advances 3:1.
Crossref
Crossref
Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa & Masahiro Mizoguchi. (2020) Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. Pharmaceuticals 13:12, pages 470.
Crossref
Crossref
Beibei Zhai, Yue Li, Sudha Sravanti Kotapalli, Jeffrey Bacha, Dennis Brown, Anne Steinø & Mads Daugaard. (2020) Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. Cell Death & Disease 11:7.
Crossref
Crossref
Evanthia Galanis, S. Keith Anderson, Erin L. Twohy, Xiomara W. Carrero, Jesse G. Dixon, David Dinh Tran, Suriya A. Jeyapalan, Daniel M. Anderson, Timothy J. Kaufmann, Ryan W. Feathers, Caterina Giannini, Jan C. Buckner, Panos Z. Anastasiadis & David Schiff. (2019) A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer 125:21, pages 3790-3800.
Crossref
Crossref
E. Schorb & C. F. Waller. 2019. Tumor Angiogenesis. Tumor Angiogenesis
609
625
.
Lila Sirven-Villaros, Véronique Bourg, Laurent Suissa, Lydiane Mondot, Fabien Almairac, Denys Fontaine, Philippe Paquis, Fanny Burel-VandenBos, Marc Frenay, Pierre Thomas & Christine Lebrun-Frenay. (2018) Bevacizumab: Is the lower the better for glioblastoma patients in progression?. Bulletin du Cancer 105:12, pages 1135-1146.
Crossref
Crossref
J. N. Jakobsen, T. Urup, K. Grunnet, A. Toft, M. D. Johansen, S. H. Poulsen, I. J. Christensen, A. Muhic & H. S. Poulsen. (2018) Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. Journal of Neuro-Oncology 137:2, pages 439-446.
Crossref
Crossref
Toni Rose Jue, Emily S. Sena, Malcolm R. Macleod, Kerrie L. McDonald & Theodore C. Hirst. (2018) A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models. Oncotarget 9:13, pages 11387-11401.
Crossref
Crossref
E. Schorb & C. F. Waller. 2018. Tumor Angiogenesis. Tumor Angiogenesis
1
18
.
E. Schorb & C. F. Waller. 2017. Tumor Angiogenesis. Tumor Angiogenesis
1
18
.
Thomas Urup, Line Mærsk Staunstrup, Signe Regner Michaelsen, Kristoffer Vitting-Seerup, Marc Bennedbæk, Anders Toft, Lars Rønn Olsen, Lars Jønson, Shohreh Issazadeh-Navikas, Helle Broholm, Petra Hamerlik, Hans Skovgaard Poulsen & Ulrik Lassen. (2017) Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer 17:1.
Crossref
Crossref
Matthew Tipping, Jens Eickhoff & H. Ian Robins. (2017) Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature. Journal of Clinical Neuroscience 44, pages 101-106.
Crossref
Crossref
CATARINA FERNANDES, ANDREIA COSTA, LÍGIA OSÓRIO, RITA COSTA LAGO, PAULO LINHARES, BRUNO CARVALHO & CLÁUDIA CAEIRO. 2017. Glioblastoma. Glioblastoma
197
241
.
Katharina J. Wenger, Marlies Wagner, Se-Jong You, Kea Franz, Patrick N. Harter, Michael C. Burger, Martin Voss, Michael W. Ronellenfitsch, Emmanouil Fokas, Joachim P. Steinbach & Oliver Bähr. (2017) Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncology Letters 14:1, pages 1141-1146.
Crossref
Crossref
Roberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, Macarena I. De La Fuente, Michael E. Ivan & Ricardo J. Komotar. (2017) The role of bevacizumab in the treatment of glioblastoma. Journal of Neuro-Oncology 133:3, pages 455-467.
Crossref
Crossref
Ellen M. P. van Coevorden-van Loon, Marijke B. Coomans, Majanka H. Heijenbrok-Kal, Gerard M. Ribbers & Martin J. van den Bent. (2017) Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. Journal of Neuro-Oncology 133:2, pages 237-246.
Crossref
Crossref
Michele Reni, Elena Mazza, Silvia Zanon, Gemma Gatta & Charles J. Vecht. (2017) Central nervous system gliomas. Critical Reviews in Oncology/Hematology 113, pages 213-234.
Crossref
Crossref
Nancy Wang, Rakesh K. Jain & Tracy T. Batchelor. (2017) New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics 14:2, pages 321-332.
Crossref
Crossref
VM Patil, R Tonse, R Kothari, A Chandrasekaran, N Pande, S Epari, T Gupta & R Jalali. (2017) Rechallenge temozolomide in glioma: A case series from India. Indian Journal of Cancer 54:1, pages 368.
Crossref
Crossref
Iwan E. Bennett, Kathryn M. Field, Christopher M. Hovens, Bradford A. Moffat, Mark A. Rosenthal, Katharine Drummond, Andrew H. Kaye & Andrew P. Morokoff. (2016) Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. Journal of Neuro-Oncology 131:2, pages 321-329.
Crossref
Crossref
Yuping Li, Mengzhuo Hou, Guangyu Lu, Natalia Ciccone, Xingdong Wang & Hengzhu Zhang. (2016) The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. PLOS ONE 11:12, pages e0168264.
Crossref
Crossref
Charlotte Aaberg-Jessen, Bo Halle, Stine S. Jensen, Sven Müller, Unni Maria Rømer, Christian B. Pedersen, Nils Brünner & Bjarne W. Kristensen. (2016) Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients. Journal of Neuro-Oncology 130:3, pages 439-448.
Crossref
Crossref
Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen & Ulrik Lassen. (2016) Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Molecular Oncology 10:8, pages 1160-1168.
Crossref
Crossref
Katharina Seystahl, Wolfgang Wick & Michael Weller. (2016) Therapeutic options in recurrent glioblastoma—An update. Critical Reviews in Oncology/Hematology 99, pages 389-408.
Crossref
Crossref
Elisabeth Bumes, Sarah Rzonsa, Markus Hutterer, Martin Proescholdt, Ulrich Bogdahn, Markus J. Riemenschneider, Martin Uhl, Christina Wendl & Peter Hau. (2015) Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab. Journal of Neuro-Oncology 127:1, pages 191-200.
Crossref
Crossref
Danilo Silva, Mayur Sharma, Telmo Belsuzarri & Gene H. Barnett. 2016. Glioblastoma. Glioblastoma
197
205
.
Enrico Franceschi, Marco Bartolotti & Alba A Brandes. (2015) Bevacizumab in recurrent glioblastoma: open issues. Future Oncology 11:19, pages 2655-2665.
Crossref
Crossref
Clara Chen, Arliene Ravelo, Elaine Yu, Rahul Dhanda & Ian Schnadig. (2015) Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices. Journal of Neuro-Oncology 122:3, pages 595-605.
Crossref
Crossref
Kien Pham, Defang Luo, Dietmar W. Siemann, Brian K. Law, Brent A. Reynolds, Parvinder Hothi, Gregory Foltz & Jeffrey K. Harrison. (2015) VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer Letters 360:1, pages 60-67.
Crossref
Crossref
Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal & David A. Reardon. (2015) Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies. Cancer 121:7, pages 997-1007.
Crossref
Crossref
Toni Rose Jue, Elizabeth Hovey, Sara Davis, Oliver Carleton & Kerrie L. McDonald. (2014) Incorporation of biomarkers in phase II studies of recurrent glioblastoma. Tumor Biology 36:1, pages 153-162.
Crossref
Crossref
Justin T. Jordan & Patrick Y. Wen. 2015. Current Understanding and Treatment of Gliomas. Current Understanding and Treatment of Gliomas
117
142
.
John P. Kirkpatrick & John H. Sampson. (2014) Recurrent Malignant Gliomas. Seminars in Radiation Oncology 24:4, pages 289-298.
Crossref
Crossref
Olivia Le Saux, Benoît You & Gilles Freyer. (2014) Antiangiogenic Therapy in Patients With HER2-Positive Metastatic Breast Cancer: A Case Series. Clinical Breast Cancer 14:3, pages e89-e94.
Crossref
Crossref
Mohamed Ali Hamza & Mark Gilbert. (2014) Targeted Therapy in Gliomas. Current Oncology Reports 16:4.
Crossref
Crossref
Betty M. Tyler, Gustavo Pradilla, Uri Hadelsberg, Hansen Bow, Ian Suk & Henry Brem. 2014. Focal Controlled Drug Delivery. Focal Controlled Drug Delivery
169
194
.
J. L. Boxerman, Z. Zhang, Y. Safriel, M. Larvie, B. S. Snyder, R. Jain, T. L. Chi, A. G. Sorensen, M. R. Gilbert & D. P. Barboriak. (2013) Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro-Oncology 15:7, pages 945-954.
Crossref
Crossref
Richard E. Kast, John A. Boockvar, Ansgar Brüning, Francesco Cappello, Wen-Wei Chang, Boris Cvek, Q. Ping Dou, Alfonso Duenas-Gonzalez, Thomas Efferth, Daniele Focosi, Seyed H. Ghaffari, Georg Karpel-Massler, Kirsi Ketola, Alireza Khoshnevisan, Daniel Keizman, Nicolas Magné, Christine Marosi, Kerrie McDonald, Miguel Muñoz, Ameya Paranjpe, Mohammad H. Pourgholami, Iacopo Sardi, Avishay Sella, Kalkunte S. Srivenugopal, Marco Tuccori, Weiguang Wang, Christian R. Wirtz & Marc-Eric Halatsch. (2013) A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4:4, pages 502-530.
Crossref
Crossref
Cécile Thirant, Julie Gavard, Marie-Pierre Junier & Hervé Chneiweiss. (2013) Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies. PROTEOMICS - Clinical Applications 7:1-2, pages 79-90.
Crossref
Crossref